Visionaries at the forefront of digital medicine and gene therapy to
discuss the commercial and patient impact of advanced innovation
in life sciences
PLEASANTON, Calif.--(BUSINESS WIRE)--
Veeva
Systems (NYSE:VEEV) today announced that Dr. William H. Carson,
president and CEO of Otsuka Pharmaceutical Development &
Commercialization, Inc. (Otsuka), and Jeffrey D. Marrazzo, CEO of Spark
Therapeutics, will be featured keynote speakers at the 2018
Veeva Commercial & Medical Summit. Otsuka and Spark Therapeutics
are at the forefront of innovation in life sciences, delivering
first-of-their-kind breakthroughs in digital medicine and gene therapy.
Otsuka’s digital medicine system is the first ever to be approved by the
U.S. Food and Drug Administration (FDA). Individuals with mental illness
and designated members of their care teams can now use a prescription
pill with an embedded sensor to track whether the medication is taken as
prescribed. Spark Therapeutics’ product is the first gene therapy
approved by the FDA to target a genetic disease and provide a one-time
treatment for people with a rare, inherited retinal disease.
The CEOs from Otsuka and Spark Therapeutics will participate in a
fireside chat to share insights on the major advancements their
companies are making to improve patients’ lives. The industry leaders
will also discuss the impact of breakthrough innovations on commercial
models in life sciences, including the opportunity to better engage with
payers, providers, and patients.
“Otsuka and Spark Therapeutics represent a new frontier in healthcare
and medical discovery that will forever change the nature of disease and
patient treatment,” said Matt Wallach, co-founder and president of Veeva
Systems and host of the fireside chat. “Dr. Carson and Mr. Marrazzo will
offer valuable perspectives into how the commercial model needs to be
reimagined in the new era of digital medicine and gene therapy.”
The 2018 Veeva Commercial & Medical Summit is expected to draw more than
1,600 life sciences professionals and experts, making it the largest
commercial and medical affairs event in the industry. The 10th
annual event takes place May 14-16, 2018 in Philadelphia and will
feature speakers from the world’s leading pharmaceutical companies and
emerging biotechs, including Bayer, Pfizer Inc., Sunovion
Pharmaceuticals, Inc., and Zimmer Biomet.
Registration for the event is complimentary for Veeva customers and
invited guests. Learn more, register, and view the full agenda at veeva.com/events/commercial-summit.
Additional Information
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow
@veevasystems on Twitter: twitter.com/veevasystems
Like
Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 600 customers, ranging from the
world's largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices in Europe,
Asia, and Latin America. For more information, visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-Q for the period ended October 31, 2017. This is available on the
company’s website at veeva.com
under the Investors section and on the SEC’s website at sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to
time.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180228005468/en/
Source: Veeva Systems Inc.